Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

New Taxes Could Help Pay For Reform, But Would Cost Political Capital
Two new taxes that could help pay for health care reform both carry political baggage. The first, a possible new tax on at least some employer-sponsored health benefits, has support from members of Congress on both sides of the aisle. But during last year"s presidential campaign, President Obama spoke out strongly against just such a plan when his opponent, Sen. John McCain suggested it, Roll Call reports. "Within weeks, Obama may find himself hawking around the country legislation that includes a provision he so ardently rejected during the campaign. Obama didn"t just oppose the exclusion. He all but drew a "read my lips" line in the sand ... "For the first time in American history, [McCain] wants to tax your health benefits," Obama said on the campaign trail. "Apparently, Sen. McCain doesn"t think it"s enough that your health premiums have doubled"" (Koffler, 6/4).
generic viagra online
Patients With Moderate To Severe Periodontitis Need Evaluation For Heart Disease Risk
Additional research is called for and patients with moderate to severe periodontitis should receive evaluation and possible treatment to reduce their risk of atherosclerotic cardiovascular disease (CVD), according to a special consensus paper by editors of The American Journal of Cardiology and Journal of Peridontology in the July 1, 2009 issue of The American Journal of Cardiology, published by Elsevier.
News of the day
Celiac Disease Four Times More Common Than In 1950s
Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology.
Endocrinology

Prevalence Of Artemisinin Monotherapies Raising Risk Of Resistence

Almost half of all artemisinin manufacturers and malaria-endemic countries are "failing to comply" with WHO requirements to sell the treatment in combination with other drugs, which is increasing the risk that malaria parasites will develop resistance to artemsinin, Nature reports. "Of the 69 manufacturers of artemisinin monotherapies that the WHO has identified, 21 have withdrawn monotherapies, and 14 say they intend to comply with the WHO"s recommendations. But the remaining 34 have not yet disclosed their intentions," Nature writes. Andrea Bosman, an official at the WHO"s Global Malaria Program, said, many manufacturers have not replied to multiple WHO requests for information. In addition, regulatory authorities in 39 of the 76 countries using malaria drugs have either complied or said they intend to comply with the WHO"s recommendations. "Artemisinin and its derivatives are the leading treatments for the disease" and are the only malaria drugs "that have not yet seen widespread resistance in malaria parasites," writes Nature. The WHO will soon publish a briefing about the full scope of the problem and will call for "governments to empower national drug-regulatory authorities to clamp down on offending companies," according to Nature. In January 2006, the WHO recommended that artemisinin be given in combination with other drugs for at least three days to reduce the chances of resistance. Now the need to move away from monotherapies has become "all the more urgent" with recent reports of resistance arising in Cambodia, Nature reports (Butler, 7/14). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009